Barclays’s Affimed AFMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-863
| Closed | -$66 | – | 5459 |
|
|
2025
Q2 | $66 | Sell |
863
-6,653
| -89% | -$4.47K | ﹤0.01% | 5110 |
|
|
2025
Q1 | $5.43K | Hold |
7,516
| – | – | ﹤0.01% | 4933 |
|
|
2024
Q4 | $8.94K | Hold |
7,516
| – | – | ﹤0.01% | 5005 |
|
|
2024
Q3 | $25.3K | Hold |
7,516
| – | – | ﹤0.01% | 4867 |
|
|
2024
Q2 | $41K | Hold |
7,516
| – | – | ﹤0.01% | 4289 |
|
|
2024
Q1 | $39.8K | Sell |
7,516
-1
| -0% | -$6 | ﹤0.01% | 4661 |
|
|
2023
Q4 | $47K | Hold |
7,517
| – | – | ﹤0.01% | 4782 |
|
|
2023
Q3 | $35.9K | Hold |
7,517
| – | – | ﹤0.01% | 3998 |
|
|
2023
Q2 | $45K | Sell |
7,517
-8,304
| -52% | -$66.6K | ﹤0.01% | 3887 |
|
|
2023
Q1 | $118K | Buy |
15,821
+4,337
| +38% | +$43.4K | ﹤0.01% | 4093 |
|
|
2022
Q4 | $142K | Buy |
11,484
+2,162
| +23% | +$37.9K | ﹤0.01% | 4028 |
|
|
2022
Q3 | $192K | Buy |
9,322
+1,091
| +13% | +$30.3K | ﹤0.01% | 3233 |
|
|
2022
Q2 | $228K | Buy |
8,231
+1,329
| +19% | +$45.5K | ﹤0.01% | 3350 |
|
|
2022
Q1 | $302K | Sell |
6,902
-11,675
| -63% | -$507K | ﹤0.01% | 3198 |
|
|
2021
Q4 | $1.02M | Sell |
18,577
-404
| -2% | -$25K | ﹤0.01% | 2821 |
|
|
2021
Q3 | $1.17M | Buy |
18,981
+7,068
| +59% | +$465K | ﹤0.01% | 2688 |
|
|
2021
Q2 | $1.01M | Sell |
11,913
-6,572
| -36% | -$600K | ﹤0.01% | 2656 |
|
|
2021
Q1 | $1.46M | Buy |
18,485
+10,892
| +143% | +$707K | ﹤0.01% | 2530 |
|
|
2020
Q4 | $442K | Sell |
7,593
-4,168
| -35% | -$196K | ﹤0.01% | 3313 |
|
|
2020
Q3 | $399K | Buy |
11,761
+710
| +6% | +$26.9K | ﹤0.01% | 3396 |
|
|
2020
Q2 | $510K | Buy |
11,051
+4,517
| +69% | +$126K | ﹤0.01% | 3324 |
|
|
2020
Q1 | $104K | Sell |
6,534
-1,928
| -23% | -$45.9K | ﹤0.01% | 4766 |
|
|
2019
Q4 | $232K | Buy |
8,462
+4,410
| +109% | +$118K | ﹤0.01% | 4930 |
|
|
2019
Q3 | $119K | Sell |
4,052
-913
| -18% | -$27.2K | ﹤0.01% | 5348 |
|
|
2019
Q2 | $142K | Buy |
4,965
+1,641
| +49% | +$55.3K | ﹤0.01% | 5401 |
|
|
2019
Q1 | $139K | Sell |
3,324
-4,372
| -57% | -$157K | ﹤0.01% | 5091 |
|
|
2018
Q4 | $240K | Buy |
7,696
+2,020
| +36% | +$75.1K | ﹤0.01% | 4451 |
|
|
2018
Q3 | $247K | Buy |
5,676
+4,337
| +324% | +$123K | ﹤0.01% | 4842 |
|
|
2018
Q2 | $22K | Sell |
1,339
-5,157
| -79% | -$109K | ﹤0.01% | 6121 |
|
|
2018
Q1 | $120K | Buy |
6,496
+5,157
| +385% | +$97.3K | ﹤0.01% | 5246 |
|
|
2017
Q4 | $17K | Hold |
1,339
| – | – | ﹤0.01% | 6345 |
|
|
2017
Q3 | $30K | Hold |
1,339
| – | – | ﹤0.01% | 5604 |
|
|
2017
Q2 | $27K | Hold |
1,339
| – | – | ﹤0.01% | 5643 |
|
|
2017
Q1 | $31K | Sell |
1,339
-560
| -29% | -$12.3K | ﹤0.01% | 5585 |
|
|
2016
Q4 | $34K | Buy |
1,899
+425
| +29% | +$9.17K | ﹤0.01% | 5367 |
|
|
2016
Q3 | $41K | Sell |
1,474
-519
| -26% | -$14.6K | ﹤0.01% | 5077 |
|
|
2016
Q2 | $49K | Buy |
1,993
+193
| +11% | +$7.06K | ﹤0.01% | 4834 |
|
|
2016
Q1 | $54K | Buy |
1,800
+845
| +88% | +$31.9K | ﹤0.01% | 4709 |
|
|
2015
Q4 | $66K | Buy |
955
+47
| +5% | +$3.19K | ﹤0.01% | 4643 |
|
|
2015
Q3 | $54K | Sell |
908
-21
| -2% | -$2.6K | ﹤0.01% | 4978 |
|
|
2015
Q2 | $121K | Buy |
+929
| New | +$89.2K | ﹤0.01% | 4535 |
|
Barclays's AFMD Position: Q3 2025 in Review
Barclays sold out of Affimed (AFMD) in Q3 2025, closing a stake of 863 shares — an estimated $66 sold.
Barclays first reported a position in AFMD in Q2 2015 and held it in 41 quarters. The position peaked at $1.46M in Q1 2021. 0 funds tracked by Wall St. Rank hold AFMD as of Q3 2025.
- Barclays reported no remaining Affimed position as of Q3 2025 after selling out during the quarter.
- Barclays sold 863 Affimed shares in Q3 2025, an estimated $66.
- Barclays first reported a position in Affimed in Q2 2015 and held it in 41 quarters.
- Barclays's Affimed position peaked at $1.46M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Affimed as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.